Can we further optimize statin therapy to increase tolerability?

Expert Opin Drug Discov. 2019 Sep;14(9):843-847. doi: 10.1080/17460441.2019.1615436. Epub 2019 May 17.

Authors

Massimiliano Ruscica¹, Zeljko Reiner², Cesare R Sirtori³

Affiliations

¹ a Department of Pharmacological and Bimolecular Sciences, Università degli Studi di Milano , Milan , Italy.
² b Department of Internal Medicine, University Hospital Centre Zagreb, School of Medicine, Zagreb University , Zagreb , Croatia.
³ c Centro Dislipidemie, A.S.S.T. Grande Ospedale Metropolitano Niguarda , Milan , Italy.

PMID: 31096808
DOI: 10.1080/17460441.2019.1615436

No abstract available

Keywords: LILRB5; PCSK9; Statin; bempedoic acid; drucebo effect; immune-mediated necrotizing myopathy; myalgia; nocebo effect.

Publication types

Editorial

MeSH terms

Cardiovascular Diseases / prevention & control*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage*
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
Myalgia / chemically induced*

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors